US Stock MarketDetailed Quotes

KPLT Katapult

Watchlist

9.4000
+0.1500+1.62%

Close Apr 25 16:00 ET

8.5500
-0.8500-9.04%

Post 17:46 ET

38.41MMarket Cap-1047P/E (TTM)

Katapult Stock Forum

Moomoo AI

Mar 15 03:10

Katapult Holdings' P/S remains below industry median despite share price surge due to its lower forecast growth. Investors see limited potential for revenue improvement, requiring a change of fortune for a higher P/S ratio.

There's No Escaping Katapult Holdings, Inc.'s (NASDAQ:KPLT) Muted Revenues Despite A 27% Share Price Rise

Moomoo AI

Jan 23 18:32

Despite Katapult Holdings' recent share price increase, its P/S ratio still trails most other firms due to a weaker revenue outlook. Investors accept this as they don't foresee any significant future revenue surprises. A turn of luck is needed for a higher P/S justification.

Improved Revenues Required Before Katapult Holdings, Inc. (NASDAQ:KPLT) Stock's 25% Jump Looks Justified

Leadbadger

Oct 12, 2023 09:34

$Katapult(KPLT.US)$
something very compelling about this chart

73351795

Aug 10, 2023 21:59

Beat Earnings Estimates again

$Katapult(KPLT.US)$

Leadbadger

Aug 9, 2023 03:56

$Katapult(KPLT.US)$ I can't believe I'm the only one over here sitting on this rocket

Leadbadger

Aug 8, 2023 04:01

$Katapult(KPLT.US)$ it would not take much to push this into a breakout

Leadbadger

Aug 5, 2023 07:06

$Katapult(KPLT.US)$ fk it.. adding more

Moomoo Breakfast US

May 11, 2022 20:23

ColumnsToday's pre-market stock movers: PTON, NIO, RBLX, U and more

Gainers:
• $Veru Inc(VERU.US)$ +25.8% (announces that in a Pre-EUA meeting held May 10 2022 FDA has agreed that the efficacy and safety data from the completed Phase 3 clinical study in hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome are sufficient to support the submission of a request for Emergency Use Authorization)
• $Desktop Metal(DM.US)$ +15.8% (prices offering of $100 mln of 6.0% convertible se...

Analysts Notebook

May 11, 2022 18:59

ColumnsTop upgrades and downgrades on 5/11

Upgrades
• $Arcturus Therapeutics(ARCT.US)$ : Baird Upgrades to Neutral from Underperform - PT $18 (from $21)
• $Arrowhead Pharmaceuticals(ARWR.US)$ : Baird Upgrades to Outperform from Neutral - PT $60 (from $71)
• $Cronos Group(CRON.US)$ : CIBC Upgrades to Outperformer from Neutral
• $HF Sinclair(DINO.US)$ : Cowen Upgrades to Outperform from Market Perform - PT $52 (from $38)
• $8x8(EGHT.US)$ : B. Riley Upgrades to Buy from Neutral - PT $13.50
• $Novanta(NOVT.US)$ : William...